Alignment Healthcare: The Star Cost $1.25 In A Day, The Cost Base Is The Bigger Problem
Alignment Healthcare faces downside as rising costs, rich benefits, and weaker ratings pressure margins. Read more on ALHC stock and why it is a Sell. - Alignment Healthcare is rated SELL with a 12-month price target of $7.23, 14% below the recent close. - The downgrade of its largest contract to 3.5 stars costs ALHC ~$1.25/share, but rising hospital costs and generous benefits drive further downside risk. - ALHC's cost structure is elevated: 2027 plans offer $823/member in extras—2.7x rivals—and stock-based compensation is 37% of adjusted EBITDA. - Valuation on peer EV/EBITDA multiples supports downside, unless cost ratios improve or the company wins its star-rating lawsuit.
